Message #9 From:
NewsBot Date: September 21, 2005 08:30:00 PM
XNOM News Xenomics' Research Partner to Make Special Presentation of Clinical Data at Prestigious World Conference on Lung Health; Leading International Health Organization Recognizes Breakthrough Potential of Xenomics Proprietary Transrenal-DNA Platform
NEW YORK--(BUSINESS WIRE)--Sept. 22, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, and its partner, Spaxen Italia, SRL, have been selected to present important new clinical evidence about the performance of its novel, noninvasive method for detection of tuberculosis (TB) at a prestigious conference in mid-October, the 36th Annual World Conference on Lung Health, organized by the International Union Against Tuberculosis and Lung Disease, to be held October 18 - 22, in Paris, France. The event is one of the international medical community's most important forums for the presentation of health and medical research.
Scientists from Xenomics' research partner Spaxen Italia will make the oral presentation at the conference. In collaboration with Xenomics' scientists, the Spaxen researchers in Rome, Italy, directed the clinical evaluation of Xenomics' proprietary Transrenal-DNA (Tr-DNA) diagnostic technology in the detection of TB. The findings in this study will be presented on October 21, in their research paper entitled "Detection of Mycobacterium Tuberculosis Transrenal DNA from Urine Samples of Patients with Pulmonary TB."
The presentation will be among a small number selected for a "Late Breaker Session," created especially to permit the presentation of very recent and particularly important research findings to the conference attendees.
The session is being co-chaired by respected officials of the U.S. Centers for Disease Control and Prevention in Atlanta, GA, Dr. Elsa Villarino and Dr. Michael F. Iademarco. Dr. Iademarco is Associate Director of Tuberculosis Elimination at CDC. The presentation will be made by Dr. Delia Goletti, an internationally recognized physician who supervised the clinical TB study under the direction of Spaxen Italia, SRL. Xenomics scientists, Dr. Samuil Umansky, Xenomics' President and Chief Scientific Officer, and Dr. Hovsep Melkonyan, Vice President, Research, collaborated on the study and are co-authors of the research paper.
The TB detection method, based on Xenomics' proprietary Transrenal-DNA (Tr-DNA) testing technology platform, is the focus of recent clinical studies at Spaxen and the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome, Italy, a strategic development partner of Xenomics.
"These latest clinical findings are quite promising and provide an excellent foundation for further clinical studies of the Tr-DNA technology. We are striving to create a new, more accurate and much safer diagnostic tool for Tuberculosis," said Dr. David Tomei, Chairman of Xenomics and President of Spaxen. "If expectations are met in the studies further along, this testing method can be expected to represent a major advance in diagnostics technology and improved healthcare services."
Xenomics CEO Dr. Randy White also called the latest clinical data a highly encouraging reinforcement of the potential value of this testing method. "It further demonstrates that our accurate, safe and relatively cost-effective TB-detection technology may offer many significant advantages compared to current diagnostic tests in use around the world for this dangerous and still all-too-common disease," he said. "These data are convincing, compelling and exciting, and we are very pleased to have the opportunity to tell industry leaders about our progress at this prestigious conference in Paris."
In a brief preview of the technical presentation, Dr. Tomei noted, "We studied 20 HIV-negative patients with culture confirmed pulmonary tuberculosis (TB). No patient exhibited clinical evidence of infection outside of the lungs, and all urine cultures for TB were negative. At the same time genetic markers of TB were detected in Tr-DNA obtained from the urine of all patients with active tuberculosis. All controls from healthy donors were negative. Also, urine specimens were obtained very early and again after two months of successful anti-TB therapy. Following therapy, all patients were found to be negative using the Tr-DNA test. Using highly specific and sensitive Tr-DNA technology, we feel that we now understand much better why others have not discovered the presence of free TB DNA in urine of pulmonary TB patients, which is a big step forward in the effort to create a more useful way to diagnose TB. The results were exceptional."
Tr-DNA technology is also in development by Xenomics for additional applications including prenatal genetic testing, tumor detection, and detection of HIV pro-viral DNA.
About the Annual World Conference on Lung Health
The 36th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (the Union) will be held at the Palais des Congres in Paris, France, October 18-22, 2005. The theme of this year's conference is "Scaling up and Sustaining Effective Tuberculosis, HIV and Asthma Prevention and control." For more information, please visit http://www.worldlunghealth.org/Conf2005/index.php.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html. Xenomics is listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
